We discuss 2 patients with extension of carcinoma in situ into the seminal vesicles and replacement of the normally present cylindroid mucosal lining. Carcinoma in situ of the ureter, bladder and prostatic ducts also was present in both patients.[ncbi.nlm.nih.gov]
The remaining three patients presented Ta or T1 relapses and underwent endoscopic resection and a new instillation of MMC.[ncbi.nlm.nih.gov]
Ep-CAM was present in all the cases with a heterogeneous staining pattern. Similarly, MUC1/episialin was variously present in 94% of the cases without a polarized staining pattern and was expressed more strongly in cases with multifocal disease.[ncbi.nlm.nih.gov]
The present study investigated the clinical efficacy of intravesical KLH in patients with carcinoma in situ (CIS) with a long-term follow-up.[ncbi.nlm.nih.gov]
The present case suggests that a long-term careful follow-up is needed to detect not only tumor recurrences but also VUR as a late complication after intravesical BCG instillation.[ncbi.nlm.nih.gov]
Grade 1 tachycardia/palpitations or chest pain each were noted in 5%. CONCLUSIONS: Oral bropirimine can induce remission of bladder CIS with acceptable toxicity at 3.0 g/day.[ncbi.nlm.nih.gov]
Grade 1 tachycardia/palpitations or chest pain each were noted in 5%. CONCLUSIONS: Oral bropirimine can induce remission of bladder CIS with acceptable toxicity at 3.0 g/day.[ncbi.nlm.nih.gov]
Grade 1 tachycardia/palpitations or chestpain each were noted in 5%. CONCLUSIONS: Oral bropirimine can induce remission of bladder CIS with acceptable toxicity at 3.0 g/day.[ncbi.nlm.nih.gov]
Diagnostic workup 6.1. Biopsy of the red velvet lesion The diagnosis of CIS can be challenging task due to the flat nature of the lesion, where the mucosa containing the lesion could be unremarkable or simply an erosion [ 21 ].[intechopen.com]
As adverse effects, bladder irritation symptoms were observed in 48.8%, pyuria in 46.5%, macroscopic hematuria in 18.6% and fever ( 37.5 degrees C) in 9.3%. There were no severe adverse effects requiring discontinuation of drug administration.[ncbi.nlm.nih.gov]
Abnormalrenalfunction also precludes use of Cisplatin-based chemotherapy regimens. B. Liver Insufficiency. No change in standard management though extent of liver disease (such as underlying cirrhosis) renders higher preoperative risk. C.[clinicaladvisor.com]
Although a 6-week treatment with intravesical BCG has been established as standard therapy in patients with CIS, there has been no consensus as to the subsequent treatment for patients in the setting of failure to initial management with BCG.[ncbi.nlm.nih.gov]
No patient discontinued therapy due to treatment-related adverse effects.[ncbi.nlm.nih.gov]
Therefore, it is considered to be the intravesical agent of choice in the treatment of CIS.[ncbi.nlm.nih.gov]
Cases that are refractory or resistant to BCG therapy are a management dilemma with various available treatment options.[ncbi.nlm.nih.gov]
All patients were previously treated with bacillus Calmette-Guerin except for 8 who were treatment naïve and 2 who received chemotherapy.[ncbi.nlm.nih.gov]
People with bladder cancer may have questions about their prognosis and survival. Prognosis and survival depend on many factors.[cancer.ca]
At present the biological behavior and prognosis of CIS remains to be completely defined.[ncbi.nlm.nih.gov]
Abstract To evaluate the clinical response to intravesical instillation therapy with bacillus Calmette-Guérin (BCG) Tokyo 172 strain for carcinoma in situ (CIS) of the bladder and subsequent patient prognosis, we reviewed data for 30 patients treated[ncbi.nlm.nih.gov]
We conclude that flow cytometric DNA analysis is a potent predictor of prognosis in cases of primary carcinoma in situ of the bladder.[ncbi.nlm.nih.gov]
. • The C-CIS group appears to have a poorer prognosis with a shorter duration of bladder preservation and a worse overall survival. 2010 THE AUTHORS. BJU INTERNATIONAL 2010 BJU INTERNATIONAL.[ncbi.nlm.nih.gov]
[…] system existence of different histologic types of bladder cancer: sqamous cell carcinoma, herein described transitional cell carcinoma adenocarcinoma, rare poorly differenciated carcinoma/small cell carcinoma, exceptional Disease cancer of the urothelium Etiology[atlasgeneticsoncology.org]
One focal area of increased tracer activity in the anterior right sixth rib of indeterminate etiology. Recommends radiographs in followups. We discussed surgery options with the doctor. He recommends the bladder be removed and so far we agree.[my.clevelandclinic.org]
[…] definition, no invasion into lamina propria Note: high grade non-invasive papillary lesions are NOT designated carcinoma in situ to avoid confusion Terminology Also known as high grade intraurothelial neoplasia (HG IUN), severe dysplasia (sometimes) Epidemiology[pathologyoutlines.com]
[…] transitional cell carcinoma of the urinary tract TCCs in other locations: transitional cell carcinoma of the renal pelvis transitional cell carcinoma of the ureter other histologies: squamous cell carcinoma of the bladder adenocarcinoma of the bladder Epidemiology[radiopaedia.org]
[…] carcinoma, exceptional Disease cancer of the urothelium Etiology most often secondary to bilharzial infection (schistosoma haematobium), may be associated with other types of long term irritations: chronic infections, calculi, treatment with cyclophosphamid Epidemiology[atlasgeneticsoncology.org]
., “Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses”, European Journal of Epidemiology , vol. 31, no. 9, 2016, pp. 811–51. Download PDF Order FREE booklet[cancervic.org.au]
Epidemiology [ 2 ] Bladder cancer is the seventh most common cancer in the UK. It is the most frequently occurring tumour of the urinary system and accounts for around 1 in every 30 new cases of cancer each year in the UK.[patient.info]
Abstract The management of CIS of the bladder consists of two complementary but separate therapeutic goals: treatment of existing disease and the prevention of recurrence.[ncbi.nlm.nih.gov]
Abstract There are theoretical limits to the efficacy of intravesical instillation of anticancer agents as a method to prevent recurrence of superficial bladder cancer.[ncbi.nlm.nih.gov]
It helps to prevent the tumor from coming back and helps prevent development of muscle invasive disease. About 6 weeks after completing the BCG, the doctor will do a cystoscopy again to make sure all of the cancer is gone.[urology.wustl.edu]
These data indicate that intravesical bacillus Calmette-Guerin is capable of producing long-term remissions of carcinoma in situ in high risk patients and may prevent or delay progression of disease necessitating cystectomy.[ncbi.nlm.nih.gov]
TUR alone is effective in preventing recurrences in approximately 50% of patients with superficial bladder cancer.[texasoncology.com]